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ABSTRACT 
 
Background: Nerve Growth Factor (NGF) and its receptors (TrkA) have been 
implicated in the neuronal remodeling present in patients with irritable bowel syndrome 
and in animal models of the disease.  Aim: To determine the involvement of NGF in 
mast cell function and colonic motor alterations in a model of ovalbumin (OVA)-
induced gut dysfunction in rats. Methods: Rats were exposed to OVA for 6 weeks. 
After the third week, animals received the TrkA antagonist K252a. Colonic mucosal 
mast cell (MMC) density and tissue levels of rat mast cell protease II (RMCPII) were 
measured. Colonic strips were obtained to assess contractile activity in vitro. Results: 
OVA exposure increased the number of MMCs and colonic RMCPII concentration. 
Spontaneous colonic contractility was similar in vehicle- and OVA-treated animals and 
was inhibited in similar proportion by K252a. Responses to carbachol were increased in 
OVA-treated rats in a K252a-independent manner. The NO-synthase inhibitor LNNA 
increased spontaneous activity in OVA-treated animals and this response was 
completely prevented by K252a. Conclusions: These observations support an 
involvement of NGF in the functional changes observed in this animal model. NGF 
receptors may represent a potential therapeutic target for the treatment of 
gastrointestinal disorders characterized by the presence of motor alterations. 
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INTRODUCTION 
 
Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disorder characterized 
by abdominal pain, alterations of the bowel habits and visceral hypersensitivity, in the 
absence of apparent organic alterations (16). IBS is highly prevalent in industrialized 
countries and may affect up to one quarter of the population (26). The underlying 
pathophysiology of IBS remains unclear. Furthermore, as there are no specific 
diagnostic tests its identification relies on the application of symptom-based criteria 
(Rome III criteria) (17), leading to potential diagnostic confusion. As a result, IBS 
therapeutics has a limited development. Therefore, the process has a tremendously 
important economic burden on health care resources for direct (e.g., diagnosis, therapy) 
and indirect (e.g., work absenteeism) costs (16). 
 
Many factors, such as external stressors, dietary constituents, genetics or intestinal 
infections have been suggested to play a role on IBS pathogenesis. Regarding the 
involvement of food in the pathophysiology of the disease, a large number of patients 
have described the exacerbation of their symptoms immediately following food 
ingestion (45). Although this onset of symptomatology could be just due to the normal 
increase of secretion and motor activity characteristic of the digestive process, in some 
patients could be related to food intolerance or alimentary allergy. While food 
intolerance is an adverse non-immune mediated reaction (e.g., an enzyme deficiency), 
alimentary allergy is an abnormal immunological response to food constituents. The 
best characterized food allergy reactions are those mediated primarily by 
immunoglobulin E (IgE) antibodies, although cell-mediated mechanisms may also be 
involved. For instance, Bischoff et al. observed that, in patients with abdominal 
symptoms suspected to be related to food allergy, some food antigens caused intestinal 
weal and flare reactions, although specific IgEs in serum were low (10). Evidence has 
been reviewed regarding the potential role of adverse food reactions in IBS (38).  For 
example, as it concerns to food allergy, it has been demonstrated that there is an 
increase in the prevalence of atopic conditions in diarrhea-predominant IBS patients 
(50). Moreover, the prevalence of IBS is higher in patients with bronchial asthma 
compared to patients with other pulmonary disorders (41). Finally, several studies 
demonstrate usefulness of oral disodium cromoglycate, an inhibitor of mast cell 
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degranulation, and elimination diets (50; 51) in diarrhea-predominant IBS patients, thus 
suggesting that part of the symptomatology observed could be related to food allergy or 
food intolerance.  
 
To better understand IBS pathophysiology, results from human and animal studies have 
to be integrated in a comprehensive manner. However, the selection of animal models 
for IBS is limited, in part because of the large, undefined, spectrum of underlying 
mechanisms of the disease. While some of the described models focus on the 
development of intestinal motor alterations characteristic of IBS, others emphasize 
visceral hypersensitivity or the stress component of the disease (37; 52). As it relates to 
models of altered motility, several strategies have been used to mimic the changes of 
colonic motor activity associated with IBS. For instance, either colonic irritation, 
experimental infections or acute and chronic stress have been used in rats and mice to 
induce colonic motor alterations reminiscent of those observed in humans with IBS (1; 
8; 29; 52). 
 
Recently, mast cells have been considered as potential key players in IBS 
pathophysiology. Mast cells are ubiquitous in the body, although they are especially 
bound within tissues that interface with the external environment, such as the skin or 
the respiratory/intestinal mucosa. They originate from precursors of the hematopoietic 
linage and circulate in blood and the lymphatic system before entering specific tissues, 
where they mature under microenvironmental influences. As a consequence, mast cells 
in different tissues exhibit heterogeneity due to locally produced growth and 
differentiation factors. In rodents, mast cells can be classified into two subtypes: 
connective tissue mast cells (CTMCs) and mucosal mast cells (MMCs). As their name 
indicate, CTMCs are mainly located in connective tissues (around blood vessels and in 
the peritoneal cavity) while MMCs are found in the intestinal and pulmonary mucosa.  
 
Mast cells produce an impressively broad array of mediators that can be subdivided 
into two classes: mediators that are preformed and stored in secretory granules (mainly 
histamine, serotonin, serine proteases, proteoglycans and some cytokines) and 
mediators that are rapidly synthesized de novo when mast cells are activated (mainly 
arachidonic acid metabolites, platelet activating factor, chemokines and some 
cytokines). Activation of mast cells occurs mainly by interaction of a multivalent agent 
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with specific IgE antibodies bound to the cell membrane. Therefore, mast cells 
represent critical effectors cells in allergic disorders and others IgE-mediated acquired 
immune responses (9). However, they are activated not only by IgE-dependent 
mechanisms, but also by several non-immunological stimuli, including 
neurotransmitters and neuropeptides (58). 
 
In the gastrointestinal mucosa, there is evidence that MMCs are closely apposed to 
nerves fibers, likely forming membrane-to-membrane contacts (48; 49). This 
relationship becomes more intimate when there is an increase in the MMC infiltrate, 
such as during IBS (61) or intestinal nematode infection in rats (49). The mechanisms 
that regulate this anatomical relationship are still unclear. It is hypothesized that 
sprouting of nerves towards mast cells is initiated by the release of mediators from mast 
cells. Blennerhassett et al. used time-lapse photomicroscopy to show that growing 
neurons were deflected towards RBL cells (a MMC-like cell line) in an apparent 
chemotactic response (11). However, it cannot be ruled out that mast cells might be 
attracted to nerves by neuropeptides. Both hypotheses could be possible as there is 
evidence that mast cells express receptors for neurotransmitters (57) and that peripheral 
nervous system neurons express receptors for mast cell-derived mediators (44). Several 
observations in vitro and in vivo evidence this bidirectional cross-talk between MMCs 
and neurons. For instance, De Jonge et al. observed that degranulation of MMCs by the 
compound C48/80 caused neuronal activation in vitro (13). Moreover, MMCs in 
primary culture were degranulated by the application of substance P and calcitonin 
gene-related peptide (CGRP) (13). Furthermore, Gottwald et al. demonstrated that the 
stimulation of the vagus nerve in the rat resulted in an increase in histamine content in 
MMCs (21). In addition, the same group observed that truncal vagotomy and sensitive 
deafferentiation by neonatal treatment with capsaicin decreased intestinal MMC 
population (22). These results suggest that, apart from an anatomical relationship, it 
exits a functional link between MMCs and the enteric nervous system (ENS).  
 
Several observations support an involvement of mast cells in the pathophysiology of 
IBS. First, many studies have evidenced a mast cell infiltration in the colon of IBS 
patients and high levels of their mediators (mainly tryptase and histamine) in 
supernatants from colonic biopsies (4). Second, the number of activated mast cells in 
close proximity to colonic nerve terminals is enhanced in IBS patients compared with 
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healthy controls (3). More interestingly, the severity and the frequency of abdominal 
pain in these patients correlate positively with these close appositions (3). Finally, 
supernatants from colonic biopsies of IBS patients, containing a variety of mast cell 
mediators, elicit functional responses (visceral hypersensitivity and alterations in 
colonic barrier function) in animals (12; 20), thus supporting an involvement in 
symptom generation in IBS patients. Moreover, murine sensory neurons in culture are 
sensitized by the same supernatants. Overall, these data point towards an important role 
of mast cell-derived mediators and the interaction mast cells-nerve fibers on the 
disturbed secretomotor and sensory functions that characterize IBS. 
 
The role of the neurotrophin nerve growth factor (NGF) and its relationship with 
MMCs in the pathophysiology of IBS is receiving increasing attention. NGF regulates 
the survival, differentiation, development and functional maintenance of both 
peripheral and central neurons. In addition, NGF also influences the development and 
activation of many hematopoietic cell types, including mast cells. The biological 
actions of NGF are mediated through two classes of cell surface receptors: the TrkA 
high-affinity, NGF-specific, receptor and the p75 low-affinity receptor, which 
presumably binds to all neurotrophins (18). Although TrkA is responsible for most of 
the neuronal effects of NGF, it has been reported that p75 acts as a coreceptor for TrkA, 
increasing its affinity for NGF (24). 
 
Within the gut, immunoreactiviy for NGF and TrkA receptors is found in the ENS (25) 
and, probably, associated with MMCs (15). NGF content is low in the normal gut, but 
inflammation results in an up-regulation of NGF mRNA (40). Although it has been 
demonstrated that several gut-resident cell types, such as epithelial cells (59), 
lymphocites (31) and mast cells (46) can produce NGF, the source of NGF in the 
gastrointestinal tract is still unclear. 
 
Apart from its physiological functions, NGF has been implicated in the neuroimmune 
alterations that characterize inflammatory and functional disorders of the gut (47).  In 
animal models of IBS, NGF has been associated to neuronal remodeling and 
recruitment of MMCs. In particular, anti-NGF treatment completely blocked the 
intestinal hypermotility induced by T. spiralis infection in rats (53) and abolished the 
increase in visceral sensitivity to colorectal distension observed in the maternal 
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separation model in rats (5). In the same model, treatment with anti-NGF prevented the 
increase of mast cells in close proximity to nerve fibers (7). In the colonic mucosa of 
IBS patients, it has been observed an enhancement of NGF immunoreactiviy associated 
to MMCs (2). The same study also showed that mucosal supernatants from IBS patients 
induced a significantly higher neuronal sprouting on cultured neuronal cell lines than 
those from healthy controls, an effect that could be reduced partly by NGF 
neutralization. From these observations, the authors suggested that mast cell-derived 
NGF may contribute to the pathophysiology of IBS (2).  
 
During the last years, our group has characterized an animal model of IBS in rats based 
on the chronic exposure to oral ovalbumin (OVA). In this model, Sprague Dawley (SD) 
rats exposed to oral OVA, without any adjuvant, for a six-week period develop an 
intestinal MMC hyperplasia together with motility alterations, reminiscent of some of 
the IBS symptoms in humans (55). Interestingly, these responses are not mediated by 
classical Th2 components like IgE, IgG, eosinophils or IL-4. This is somehow 
unexpected since SD rats have been widely used as a model of OVA-induced allergic 
response. However, in most of these models, OVA sensitization is done by parenteral 
injection of the peptide and only the final challenge is given orally. Therefore, the 
chronic oral exposure to OVA represents a valid approach to IBS non-atopic patients, 
whose symptoms are associated with the ingestion of particular foods.  
 
In this model, we have also observed that oral exposure to OVA causes NGF 
overexpression in the colon, as assessed by conventional PCR (54). In addition, 
pretreatment with the mast cell stabilizer ketotifen prevents OVA-induced NGF 
overexpression. However, perhaps the most interesting observation is that there is a 
positive correlation between the number of colonic MMCs and the level of expression 
of NGF. All together, these data point towards a functional link between MMCs and 
NGF, thus supporting the observations derived from other animal models or from IBS 
patients.  
 
From these observations, it was considered of interest to further explore the role of 
NGF and its receptors in the colonic motor changes observed during the chronic oral 
OVA exposure in rats.  
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HYPOTHESES AND AIMS 
 
Taking into consideration the background exposed, the working HYPOTHESES of the 
present study are: 
 
(i) Colonic MMCs are involved in the changes in NGF expression observed 
during the chronic oral exposure to OVA in rats and might represent a 
source of NGF. 
NGF is increased in the colonic mucosa of IBS patients and part of 
the cells showing NGF immunoreactivity are MMCs (2). However, the 
observations made in animal models of the disease are disparate, 
showing both mast cell-dependent and -independent variations in the 
content of NGF (5; 47). The chronic oral OVA exposure model seems 
appropriate to investigate these questions since, as mentioned, it also 
shows changes in mast cells and NGF expression (54).   
 
 
(ii) OVA-induced colonic motor alterations implicate NGF-dependent 
mechanisms. 
Previous studies demonstrated functional and morphological 
effects of treatment with anti-NGF antibodies in relevant animal 
models of IBS.  In particular, our group has demonstrated that 
immunoneutralization of NGF in Trichinella spiralis-infected rats 
prevented most of the intestinal motor abnormalities induced by the 
nematode (53).  
 
 
From these hypotheses, the AIMS of the present study are: 
 
(i) To further characterize the alterations of colonic motility associated to 
chronic oral OVA exposure in rats. 
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(ii) To investigate the implication of NGF in the development of OVA-induced 
motor changes by the use of the alkaloid K252a, an antagonist of the high-
affinity NGF receptor TrkA. 
 
(iii) To determine, in the same animal model, the colonic expression of NGF and 
its possible relation with MMCs. 
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MATERIALS AND METHODS 
 
Animals 
 
Adult (5 week-old at arrival), specific pathogen free (SPF), Sprague-Dawley (SD) male 
rats were used (Charles River, Les Oncins, France). Animals had free access to water 
and a standard pellet diet that did not contain any trace of OVA or any other egg 
derivative (A04; Safe, Augy, France). During all the experiment, rats were maintained 
under conventional conditions in a light (12h/12h light-dark cycle) and temperature 
controlled (20-22ºC) room, in groups of two per cage. Animals were acclimatized to the 
new environment for 1 week before starting any experimental procedure. All the 
experimental protocols were approved by the Ethical Committee of the Universitat 
Autònoma de Barcelona.   
 
Experimental protocols 
 
Oral exposure to ovalbumin (OVA) and treatment with K252a   Rats received OVA 
by oral gavage (1mg/mL, 1 mL/rat, n=16). Treatment was performed daily during a 6- 
week period (43). A group of rats receiving vehicle (1 mL/rat, n=13) was used as 
control (Unexposed). After the third week, six of the animals receiving OVA and five 
animals receiving vehicle were treated subcutaneously with K252a (50 µg/kg). 
Treatment with K252a was performed daily for 4 weeks. The remaining of the rats (10 
exposed animals and 8 unexposed) were used as control groups in which the treatment 
protocol was the same but K252a was replaced by the corresponding vehicle (1 mL/kg, 
sc). Animals were euthanized by decapitation 10 days after the end of the OVA 
exposure period. Tissue samples from colon were removed and either fixed in 4 % 
paraformaldehyde for immunohistochemical studies or frozen in liquid nitrogen and 
stored at -80ºC until analysis. 
 
Organ bath 
 
Full thickness preparations were obtained from the mid portion of the colon, cut 1 cm 
long and 0.3 cm wide and hung to record circular muscle activity using a standard 
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organ bath system.  Strips were mounted under 1 g tension in a 10-mL muscle bath 
containing carbogenated Krebs solution (95% O2 – 5% CO2) maintained at 37 ± 1ºC. 
The composition of Krebs solution was (in mmol/L): 10.10 glucose, 115.48 NaCl, 
21.90 NaHCO3, 4.61 KCl, 1.14 NaH2PO4, 2.50 CaCl2, and 1.16 MgSO4 (pH 7.3–7.4). 
One strip edge was tied to the bottom of the muscle bath using suture silk and the other 
one to an isometric force transducer (Harvard VF-1 Harvard Apparatus Inc., Holliston, 
MA, USA). Output from the transducer was fed to a PC through an amplifier. Data 
were digitalized (25 Hz) using Data 2001 software (Panlab, Barcelona, Spain). Strips 
were allowed to equilibrate for about 1h. After this period, contractile responses to 
carbachol (CCh; 0.1 - 10 µM) and the NO inhibitor NG-nitro-L-Arginine (LNNA; 1 
mM) were assessed. For CCh, cumulative concentration-response curves, with a 5 min 
interval between consecutive doses, were constructed. For LNNA, spontaneous activity 
was recorded during a 10-minutes period after the addition of the drug. 
  
To determine spontaneous contractile activity, the preparation tone was measured for 
15 minutes and the mean value (in g) determined. To determine the effects of CCh, the 
maximum peak from the basal tone was measured after each concentration tested. To 
measure the response to LNNA, the 10 minutes mean of the strip tone before the drug 
administration was compared with the 10 minutes mean of the strip tone after the 
administration.  
 
Immunohistochemistry (IHC) 
 
Immunodetection of RMCPII and NGF was carried out on paraformaldehyde-fixed 
colonic samples using a monoclonal antibody anti-RMCPII (Moredun Animal Health, 
Edinburgh, UK) and a polyclonal rabbit anti-NGF (ab1526; CHEMICON International, 
Temecula, USA). Antigen retrieval for NGF was achieved by processing the slides in a 
pressure cooker at full pressure, for 10 minutes, in 10 mM citrate solution. The 
secondary antibodies included biotinylated horse antimouse IgG (BA-2000; Vector 
Laboratories, Burlingame, CA, USA) and biotinylated swine antirabbit Ig (E0353; 
DAKO, Carpinteria, CA, USA), as appropriate. Detection was performed with 
avidin/peroxidase kit (Vectastain ABC kit; Vector Laboratories, Burlingame, CA, USA) 
and counterstaining with haematoxylin. Specificity of the staining was confirmed by 
omission of the primary antibody. When performing IHC for NGF, mouse submaxillary 
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glands were used as a positive control. Slides were viewed with an Olympus BH-2 
microscope. For MMC quantification, at least 20 non-adjacent X40 fields of colonic 
mucosa were randomly selected and the number of RMCPII-immunopositive cells 
counted manually. Procedures were carried out using coded slides to avoid bias.  
 
ELISA 
 
Protein was extracted from colonic tissue samples using lysis buffer (50 mM HEPES, 
0.05 % Triton X-100, 0.0625 mM PMSF and the Mini Complete protease inhibitor 
Roche) and RMCPII concentration was determined by ELISA using a commercial kit 
(Moredun). Total protein was determined using the Bradford assay kit (BIO-RAD, 
Hercules, CA, USA).  
 
Chemicals 
 
OVA (OVA Grade V; A5503) was purchased from Sigma-Aldrich (St.Louis, MO, USA) 
and dissolved in saline solution. K252a (Tocris Bioscience, Ellisville, MO, USA) was 
reconstituted in 8.75 % ethanol in milli-q water. LNNA and CCh (Sigma-Aldrich) were 
dissolved in distilled water as stock solutions. 
 
Statistics 
 
All data are expressed as mean ± SEM. Results from the organ bath are presented as 
raw data (g of force). EC50 for CCh was calculated by non-linear regression to a 
sigmoidal equation (GraphPad Prism 4.01, San Diego, California, USA). Statistical 
analysis was performed with one-way or two-way ANOVA, as appropriate, followed, 
when necessary, by a post hoc Newman-Keuls test. Differences between groups were 
considered statistically significant when P < 0.05. 
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RESULTS 
 
Colonic mucosal mast cell count 
 
MMCs were clearly identified as cells located in the mucosa and submucosa of the 
colon, with an irregular, brown-stained, cytoplasm (Fig. 1). No staining was observed 
in other areas of the colon. Omission of the primary antibody resulted in the total 
absence of immunoreactivity. The density of MMCs was relatively low in control 
conditions (3.8±0.5 cells/field), in agreement with that previously described in similar 
experimental conditions (55). Oral exposure to OVA increased by 40% the number of 
colonic MMCs, although statistical significance was not reached (Fig. 1). Treatment 
with K252a did not affect the density of MMCs in control conditions or the increase 
observed during OVA exposure (Fig. 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  A: Photomicrographs showing RMCPII-immunopositive cells in colonic mucosa 
(X400). A.1: Control rat. A.2: OVA-treated rat. Note the higher number of positive mast 
cells in the OVA-treated compared with the unexposed rat.  B: Density of MMCs in the 
different experimental groups. Data are mean ± SEM; n=2-8 per group (ANOVA). 
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Colonic RMCPII content 
 
Colonic RMCPII content was low in control conditions and levels were not affected by 
treatment with K252a (Fig. 2). OVA exposure increased RMCPII levels by 65% when 
comparing the control-control and the OVA-control groups, and by 60 % when 
comparing control-K252a and the OVA-K252a groups (Fig. 2). Overall, a two-way 
ANOVA analysis revealed an OVA effect (P=0.022), although statistical significance 
among individual groups was not achieved.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2  RMCPII content in colonic extracts from the different experimental groups. Data 
are mean ± SEM; n=5-10 per group. #: P=0.075 vs. control-control (ANOVA). 
 
 
 
Colonic spontaneous contractility 
 
Spontaneous contractile activity was similar in vehicle- and OVA-exposed animals 
(control: 0.53±0.06 g; OVA: 0.51±0.03 g; P>0.05; Fig. 3). Treatment with K252a 
decreased spontaneous activity in OVA-exposed animals (0.35±0.05 g, P<0.05 vs. 
OVA) and similar tendency was observed in the vehicle-treated group (0.40±0.05 g; 
P=0.07 vs. control; Fig.3). 
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Figure 3 Colonic spontaneous contractile activity in the different experimental groups. Data 
are mean ± SEM; n=5-10 per group. *: P<0.05 vs OVA-control; #: P=0.074 vs. control-
control (ANOVA). 
 
 
 
Contractile responses to carbachol 
 
In control conditions, CCh elicited a concentration-dependent contractile response with 
an estimated EC50 of 8.7 10-4±4.5 10-4 mM (Fig. 4). OVA exposure significantly 
increased the responses to CCh, leading to a right-shift of the concentration-response 
curve and an estimated EC50 of 1.7 10-4±4.1 10-5 mM (P<0.05 vs. control; Fig. 4). 
Treatment with K252a did not affect the responses to CCh, neither in vehicle- nor in 
OVA-exposed animals (Fig. 4).  
 
 
Contractile responses to LNNA 
 
Overall, LNNA showed a tendency to increase spontaneous activity in all experimental 
groups. However, significance was only achieved in the OVA-control (basal: 0.5±0.1 g, 
LNNA: 0.9±0.1 g, P<0.05; Fig. 5). Treatment with K252a completely prevented 
LNNA-induced hyperactivity in OVA-treated animals (Fig. 5). In these conditions, 
effects of LNNA were similar as those observed in the groups not exposed to OVA (Fig 
5).  
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Figure 4  Contractile responses to carbachol. A: Concentration-response curves. Note that 
oral exposure to OVA leads to a right-shift of the concentration-response curve, an effect 
not modified by treatment with K252a. B: Estimated EC50 for the different experimental 
groups. Data are mean ± SEM; n=5-10 per group. *: P<0.05 vs. respective control 
(ANOVA).  
 
 
 
 
 
0.0000
0.0003
0.0006
0.0009
0.0012
0.0015
* *
Control
Control
Control
K252a
OVA
Control
OVA
K252a
C
C
h 
EC
50
(m
M
)
-6 -5 -4 -3 -2
0
1
2
3
4
5
6
OVA
CONTROL
OVA
K252a
CONTROL
CONTROL
CONTROL
K252a
Log CCh Dose (mM)
M
ax
im
al
 e
ffe
ct
 (g
)
B 
A 
16 
  
 
 
 
 
 
 
 
 
 
Figure 5  Effect of NO blockade with LNNA on spontaneous contractility in the 
different experimental groups. Data represent the change in spontaneous activity over 
the control period (before LNNA addition) and are mean ± SEM; n=5-10 per group. *: 
P<0.05 vs. other experimental groups (ANOVA). 
 
 
 
Immunohistochemistry for NGF 
 
Within the colon, immunoreactivity for NGF was detected in the submucosal and 
myenteric plexuses (Fig. 7). The epithelium and some crypts also showed a diffuse 
staining. Within de villi, there were scarce cells, of undetermined type, showing NGF-
like immunoreactivity (Fig. 7). No labelling was detected in the muscle layers. No 
differences in the staining pattern or intensity were observed between OVA- and 
vehicle-treated animals or associated to the treatment with K252a (Fig 7). All 
immunoreactivity was absent in sections in which the primary antibody was omitted, 
thus confirming the specificity of the staining. Staining was intense and well localized 
in positive controls from mouse submaxillary glands. 
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Figure 6. Photomicrographs showing 
NGF-like immunoreactivity in colonic 
tissues. A: Control-control rat. B: 
OVA-control. C: Control-K252a. D: 
OVA-K252a. E: Negative control 
(omission of the primary antibody).  
Labelling for NGF is detected in the 
submucosal and myenteric plexuses, 
epithelium and crypts, and in scarce, 
unidentified cells within the villis. 
Note that no differences in the staining 
pattern or intensity are observed 
between OVA- and vehicle-treated 
animals or associated to the treatment 
with K252a. 
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DISCUSSION 
 
This study shows that oral exposure to OVA in rats induces a moderate MMC 
infiltration in the colon, increases colonic MMC activity, as assessed by tissue levels of 
RMCPII, and causes colonic motor alterations. In addition, we also show evidence that 
NGF is implicated in colonic spontaneous motor activity and mediates some of the 
motor alterations induced by OVA. 
 
As we have previously demonstrated, chronic exposure to oral OVA in rats leads to 
colonic dysfunction in the absence of any systemic allergic response, as revealed by the 
absence of circulating anti-OVA IgEs or IgGs (55). In addition, oral exposure to OVA 
does not affect the number of eosinophils in the mucosal intestine or IL-4 concentration 
in serum. Therefore, the mechanism by which OVA, or OVA digested fragments, is 
able to recruit and stimulate MMCs is Ig-independent. Hence, chronic oral exposure to 
OVA in rats represents a good model mimicking the condition of patients with 
symptoms of IBS who suffer from food hypersensitivity not mediated by intestinal 
mucosal mechanisms involving IgEs (23).  
 
The results of this study confirm that OVA increases RMCPII levels within the colonic 
wall, as an indicator of MMC activity. This is in agreement with data obtained in 
colonic biopsies from IBS patients in which the number of degranulating MMCs was 
significantly increased with respect to healthy subjects (3). In parallel to the 
enhancement of RMCPII levels, we observed a moderate increase in the number of 
MMCs in the colon of rats exposed to oral OVA, similarly to that described previously 
in the same model (55). At this point, it should be mentioned that authors differ when it 
comes to MMC hyperplasia in the colon of IBS patients. While Barbara et al. observed 
a major MMC density in IBS patients with respect to healthy controls (3), Cenac et al. 
found no differences (12). However, both studies demonstrated an increase in the 
amount of tryptase, a MMC mediator, released from IBS biopsies, thus suggesting 
higher levels of MMC activation and degranulation. In animal models of the disease, 
and in particular in the neonatal maternal deprivation model, opposite results, as it 
relates to colonic MMC hyperplasia, have also been obtained in two different studies (5; 
56). Nevertheless, both studies demonstrated the importance of MMC degranulation in 
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the onset of visceral hyperalgesia, one of the main symptoms of IBS. Our results 
support these observations. Although we did not observe a significant MMC 
hyperplasia associated to OVA exposure, tissue levels of RMCPII were increased, 
indicating a higher degree of mast cell activation in OVA-treated animals. Overall, 
these observations support a role for MMC mediators in the colonic secretomotor and 
sensory abnormalities that characterize IBS. 
 
One of the most common symptoms that characterize IBS is altered colonic motility 
(27). The results of our study clearly show that rats exposed to OVA have colonic 
motor alterations. As previously described in this model (55), contractile responses to 
CCh were enhanced, thus indicating an increased excitability of the muscle to the 
cholinergic stimulation, which represents the major excitatory neurotransmitter within 
the ENS. Histological examination of the tissues excludes a muscle hypertrophy as a 
potential cause for this hyperesponse (data not shown). Interestingly, these increased 
excitatory responses are associated also to an enhanced NO-dependent inhibitory tone, 
as suggested by the increase in spontaneous contractility observed during the blockade 
of NO production with LNNA. Previous studies evidenced that rat’s colonic 
spontaneous motility in vivo is mediated by neuronal release of acetylcholine and 
partially suppressed by the constitutive release of NO (32). Hence, seems feasible to 
speculate that the OVA-induced increase in the nitrergic inhibitory tone might represent 
a mechanism to compensate the enhancement of cholinergic excitatory responses. 
 
A possible explanation for this OVA-induced increase in cholinergic excitability could 
be related to an excited-activated state of MMCs, as suggested by the higher tissue 
concentration of RMCPII observed in OVA-treated animals. In fact, a previous study 
found a significant positive correlation between the colonic response to CCh and 
RMCPII content (55). Following the same line, there is evidence that mast cell 
mediators can be released in close proximity to the ENS causing neuronal excitability. 
For example, in small intestine submucosal neurons of milk-sensitized guinea-pigs, 
exposure to β-lactoglobulin increased excitability in nerve cells including cholinergic 
neurons, an event that could be significantly reduced by the mast cell stabilizer 
ketotifen (35). In that study, the authors identified histamine, prostaglandins and 
leukotrienes as the mast cell mediators involved in the excitatory responses to β-
lactoglobulin. This is in agreement with another study that demonstrated that histamine 
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caused acetylcholine release in the guinea-pig ileum (42). However, ENS-mediated 
motor responses may also be elicited by other MMC mediators. For instance, Gao et al. 
demonstrated that mast cell tryptase evoked protease-activated receptor 2 (PAR-2)-
dependent excitatory responses in guinea pig enteric neurons (19). Moreover, they also 
observed that part of the PAR-2 sensitive neurons expressed immunoreactivity for 
nitric oxide synthase, suggesting a modulation of the nitrergic inhibitory tone. 
Therefore, MMC mediators, including proteases, might also mediate direct changes in 
the nitrergic system, an effect that can not be excluded in the present study.  
 
In animals models of IBS, both mast cell degranulation and NGF have been implicated 
in gut dysfunction and, indeed, NGF has been suggested to be mast cell derived (5; 6). 
For instance, NGF immunoneutralization reverses colonic hypersensitivity in rats with 
colitis or that have experienced neonatal maternal deprivation (5; 14; 56). Along the 
same line, our group has described that colonic NGF expression is increased by OVA 
exposure (54). In addition, we have found a positive correlation between the number of 
MMCs and the expression of NGF, thus suggesting a functional link between MMCs 
and the neurotrophin within the colon. In order to expand these observations to the 
protein level and to elucidate the colonic source of NGF, IHQ for the neurotrophin was 
assessed in colonic samples. Although we were able to see specific NGF staining, with 
similar patterns of distribution as those previously reported (63), we did not find any 
obvious differences in staining, intensity or distribution among the different 
experimental groups. Colonic immunoreactivity for NGF was localized mainly in 
epithelial cells at the mucosal surface and in the submucosal and myenteric plexuses, in 
agreement with previous observations (25; 47; 63). In colonic biopsies of patients with 
functional and inflammatory gastrointestinal disorders, NGF immunoreactivity has 
been localized in MMCs (2; 15). In spite of that, we have been unable, so far, to detect 
NFG immunoreactivity in MMCs during double labeling studies (data not shown). 
These results might look unexpected given that we had previously found a positive 
correlation between the density of MMCs and NGF expression, as assessed by 
conventional PCR (54). However, a recent study assessing changes in colonic NGF 
content in a colitis model in rats found evidence for the presence of a higher molecular 
weight form of the neurotrophin, probably a proNGF, in isolates from cultured mast 
cells (47). The authors showed the expression of a 13 kDa NGF-like protein 
(corresponding to the mature form of the neurotrophin) in the inflamed mucosa and, by 
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PCR from laser microdissected cells, evidenced that NGF was principally synthesized 
by epithelial cells. However, neither lamina propria cells nor cultured MMCs expressed 
mRNA for NGF or produced the 13 kDa NGF form. Therefore, the authors suggested 
that MMCs could represent a source of the NGF precursor, although the conditions of 
its release and further processing to the final mature form are still unknown. Studies on 
cultured rat peritoneal mast cells support this hypothesis since cells extracts contained 
73 kDa NGF immunoreactive-like species but not the mature form of the peptide, thus 
suggesting that mast cells are a source of NGF precursors (46). Hence, although not 
confirmed immunohistochemically, the positive correlation between the density of 
MMCs and the expression levels of NGF could represent a true functional link between 
the production of the neurotrophin in the gut and MMCs. Further studies are needed to 
clarify the potential role of MMCs on the enhanced NGF levels in OVA-exposed rats.  
 
In this study, we aimed also to elucidate the functional implication of NGF in the 
colonic motility alterations characteristic of the model. A role for NGF on 
gastrointestinal motor alterations in IBS models has been previously described in rats 
infected with Trichinella spiralis in which anti-NGF treatment completely blocked the 
development of spontaneous hypermotility in the small intestine (53). In order to study 
the involvement of NGF in OVA-induced colonic motor dysfunction in rats, we used a 
pharmacological approach based on the blockade of NGF receptors with K252a. K252a 
is an inhibitor of protein kinase C and cyclic nucleotide-dependent kinases that 
functions as an antagonist of the high-affinity NGF receptor TrkA (28). For instance, 
K252a was effective inhibiting NGF-induced neuritic outgrowth in PC12 cells in vitro 
(30) and NGF-mediated effects in different in vivo models (39; 62). 
  
In our conditions, treatment with K252a decreased spontaneous colonic motility and 
prevented the enhancement of the nitrergic inhibitory tone induced by oral exposure to 
OVA, thus indicating a role for the neurotrophin in the regulation of colonic motility. It 
is feasible to speculate that a tonic NGF-dependent stimulation might be necessary to 
maintain the ENS at optimal functional and morphological conditions. Therefore, the 
persistent blockade of NGF receptors, as performed here, might lead to changes in the 
regulatory mechanisms implicated in normal motor activity or the alterations induced 
by OVA. It has been demonstrated that NGF not only produces structural responses in 
neurons but also functional changes as there are substantial evidences that this 
22 
  
neurotrophin regulates neuropeptides synthesis and release. Rat myenteric neurons 
express the high-affinity receptor TrkA (33) and it has to be taken into consideration 
that NGF has been reported to significantly enhance neurite arborizations and neuronal 
sprouting in cell cultures (2; 64). Lindsay et al. reported that NGF regulated the 
expression of mRNAs encoding the precursors of substance P and calcitonin gene-
related peptide (CGRP) in adult dorsal root ganglion neurons (34). Moreover, NGF 
immunoneutralization significantly reduced the colonic content of CGRP in rats (40). 
Therefore, we can hypothesize that K252a is binding to TrkA receptors of enteric 
neurons preventing NGF-mediated functional and/or structural effects within the ENS. 
However, it remains unclear why enhanced CCh responses during OVA exposure are 
not affected by K252a treatment since enteric cholinergic neurons also express TrkA 
receptors (33). A possible answer could be that OVA-induced dysmotility implies the 
recruitment of additional NGF/TrkA-independent mechanisms. 
 
The dose of K252a used here is similar to that used in different studies showing 
biological effects in vivo, thus suggesting and effective blockade of the receptors (39; 
62). A recent study demonstrated that treatment with K252a or with TrkA antisense 
oligonucleotides blocks in similar manner chronic stress-induced visceral 
hypersensitivity to colorectal distension in rats (63), indicating that the biological 
effects of K252a are associated to the selective blockade of TrkA receptors. However, 
K252a might bind to other Trk receptors present in the ENS (60). Therefore, it cannot 
be ruled out that the effects observed might be, at least partially, associated to the 
blockade of other neurotrophins receptors. Nevertheless, the similar effects obtained 
during the pharmacological blockade with K252a, the treatment with TrkA antisense 
oligonucleotides and the direct immunoneutralization of NGF (63) suggest that NGF-
mediated effects within the gastrointestinal tract are predominantly mediated through 
TrkA-dependent mechanisms.   
 
Expression of TrkA receptors within the gut is not only restricted to the ENS. 
Preliminary studies of our group suggest that lamina propria cells from rat colon 
express TrkA receptors and the majority of these cells are also RMCPII-
immunoreactive, thus being positively identified as MMCs (data not shown). These 
data are in agreement with studies that demonstrate that NGF is able to degranulate 
mast cells (36). Therefore, another mechanism of action of K252a could be preventing 
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MMC degranulation. Since during the degranulation process mast cells might release 
potential precursor forms of NGF (46), treatment with K252a would diminish the 
neurotrophin availability within the colon. As a consequence, direct effects of K252a 
on TrkA receptors on enteric neurons would be boosted by the reduced NGF 
availability. In addition, apart from NGF, the release of other MMC mediators would 
also be reduced, leading to a state of diminished interaction with the ENS.  
 
In summary, this study shows that oral exposure to OVA increases colonic MMC 
density and degranulation and causes alterations of colonic motor activity. Although we 
had previously demonstrated that OVA exposure results in an increase in colonic NGF 
expression, immunohistochemical studies did not reveal any effect of OVA exposure 
on NGF immunoreactivity. Nevertheless, pharmacological studies using the TrkA 
antagonist K252a suggest an involvement of NGF in OVA-induced colonic motor 
alterations. Overall, our study highlights a potentially important role for NGF-
dependent mechanisms on colonic motor alterations associated to inflammatory and 
functional disorders of the gut. Therefore, NGF receptors could represent a therapeutic 
target for the treatment of gastrointestinal disorders characterized by altered motility. 
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CONCLUSIONS 
  
In conclusion, the results from this study show that: 
 
i) Colonic MMC density and activity, as assessed by RMCPII content, is 
increased by oral exposure to OVA.  
 
ii) Chronic exposure to oral OVA causes colonic motor alterations 
characterized by increased cholinergic responses and NO-dependent 
inhibitory tone. MMC mediators seem to play a pivotal role on these motor 
alterations.  
 
iii) Spontaneous colonic contractile activity in the rat depends, at least partially, 
on NGF/TrkA pathways. 
 
iv) NGF/TrkA-dependent mechanisms mediate some of the colonic motor 
alterations associated to the OVA model. The blockade of TrkA receptors 
might have a direct effect on enteric neurons and/or prevent the release of 
MMC mediators to the ENS, thus affecting colonic motility.  
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PERSPECTIVES 
  
From the results obtained in this study, follow-up studies should further explore: 
 
i) If OVA exposure is indeed associated to an increase in colonic NGF content. So 
far, at the mRNA level there seems to be an increase in the expression of 
colonic NGF. However, we have been unable to confirm this using 
immunohistochemistry. Other molecular tools, namely Western-blot, might be 
of help determining if mRNA changes are translated at the protein level. These 
techniques would also allow to assess the molecular forms of NGF (precursors 
vs. mature form) present in the colon.  
 
ii) The potential role of MMCs as a cellular source of NGF in the colon. A 
combination of double immunofluoresence (for RMCPII and NGF) and PCR 
detection of mRNA for NGF in MMCs isolated through laser capture 
microdissection might be of help answering this question. 
 
iii) The presence of phenotypic changes in the colonic innervation of OVA-treated 
rats. The expression of different neuronal markers, such as neuronal specific 
enolase (NSE) and growth-associated protein 43 (GAP-43), can be used to 
assess OVA-induced neuroplastic changes in the colon, particularly at the level 
of the mucosa (assessing the density of nerve terminals and their proximity to 
MMCs) and the myenteric plexus.  
 
iv) If chronic oral OVA exposure results in other functional alterations besides 
dysmotility. It might be of particular interest to assess changes in visceral 
sensitivity. Visceral hyperalgesia to colorectal distension is one of the hallmarks 
of IBS and is a representative surrogate marker in most of the animal models of 
the disease. Both NGF and MMCs have been implicated in sensory responses 
leading to visceral hyperalgesia. These studies would increase the validity of the 
OVA exposure model and further characterize the involvement of NGF and 
MMCs in visceral sensitivity. 
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